Walleye Capital
URGN icon

Walleye Capital’s UroGen Pharma URGN Stock Holding History

Walleye Capital’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-190,452
Closed -$3.8M – 5169
2025
Q3 		$3.8M Sell
190,452
-155,710
-45% -$2.8M 0.01% 1102
2025
Q2 		$4.74M Buy
+346,162
New +$3.32M 0.02% 893
2024
Q3 		– Sell
-57,610
Closed -$967K – 5908
2024
Q2 		$967K Buy
+57,610
New +$819K ﹤0.01% 2885
2024
Q1 		– Sell
-27,218
Closed -$408K – 5920
2023
Q4 		$408K Buy
+27,218
New +$353K ﹤0.01% 3108

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Walleye Capital's URGN Position: Q4 2025 in Review

Walleye Capital sold out of UroGen Pharma (URGN) in Q4 2025, closing a stake of 190,452 shares — an estimated $3.8M sold.

Walleye Capital first reported a position in URGN in Q4 2023 and held it in 4 quarters. The position peaked at $4.74M in Q2 2025. 167 funds tracked by Wall St. Rank hold URGN as of Q4 2025.

  • Walleye Capital reported no remaining UroGen Pharma position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 190,452 UroGen Pharma shares in Q4 2025, an estimated $3.8M.
  • Walleye Capital first reported a position in UroGen Pharma in Q4 2023 and held it in 4 quarters.
  • Walleye Capital's UroGen Pharma position peaked at $4.74M in Q2 2025.
  • 167 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.